U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis [Internet]. Geneva: World Health Organization; 2018.

Cover of WHO treatment guidelines for isoniazid-resistant tuberculosis

WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis [Internet].

Show details

Glossary

The following definitions refer to common terms as used in these guidelines:

Isoniazid-resistant TB (Hr-TB),

refers to Mycobacterium tuberculosis strains with resistance to isoniazid and susceptibility to rifampicin confirmed in vitro. Definitions and terms used herein have been described elsewhere1,2

Poly-resistance

refers to resistance to more than one first-line anti-TB drug, other than isoniazid and rifampicin together.

Drug-susceptibility testing (DST)

refers to in vitro testing using either phenotypic methods to determine susceptibility or molecular techniques to detect resistance-conferring mutations to a particular medicine. Policy guidelines on the use of phenotypic and molecular tests for the detection of resistance to isoniazid has been published by WHO3,4,5

Previously treated

refers to patients who have received one month or more of anti-TB medicines in the past.1 Previously treated cases may have been treated with an individualized regimen including fluoroquinolones or injectable agents in addition to first-line TB medicines.6

New case

is defined as a newly registered episode of TB in a patient who has never been treated for TB or has taken anti-TB medicines for less than 1 month.

Treatment outcome

definitions used in these guidelines, and the term relapse, refer to those used for patients without rifampicin-resistant tuberculosis, unless otherwise specified1

Serious adverse event (SAE)

is defined as an adverse event which either leads to death or a life-threatening experience; to initial or prolonged hospitalization; to persistent or significant disability; or to a congenital anomaly. SAEs that do not immediately result in one of these outcomes but that require an intervention to prevent permanent impairment of a body function or damage to a body structure are included. The management of SAEs may require termination of the drug suspected of having caused the event7

1

Definitions and reporting framework for tuberculosis – 2013 revision (WHO/HTM/TB/2013.2). Available from: http://apps​.who.int/iris​/bitstream/10665​/79199/1/9789241505345_eng.pdf. Geneva: World Health Organization. 2013.

2

Guidelines for surveillance of drug resistance in tuberculosis - 5th ed [WHO/HTM/TB/2015.13]. Available from: http://apps​.who.int/iris​/bitstream/10665​/174897/1/9789241549134_eng.pdf. Geneva: World Health Organization. 2015.

3

Policy statement: Liquid media for culture and DST. The use of liquid medium for culture and DST, 2007. Available from: http://www​.who.int/tb​/areas-of-work/laboratory​/policy_liquid​_medium_for_culture_dst/en/. Geneva: World Health Organization. 2007.

4

Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Available from: http://www​.who.int/tb​/publications/2008/whohtmtb_2008_392​/en/. 2008.

5

WHO policy statement: molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. Available from: http://www​.who.int/tb​/areas-of-work/laboratory​/line_probe_assays/en/. Geneva: World Health Organization, 2008.

6

Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis (WHO/HTM/TB/2014.11). Available from: http://apps​.who.int/iris​/bitstream/10665​/130918/1/9789241548809_eng.pdf. Geneva: World Health Organization. 2014.

7

Active tuberculosis drug-safety monitoring and management (aDSM): framework for implementation (WHO/HTM/TB/2015.28). Available from: http://apps​.who.int/iris​/bitstream/10665​/204465/1/WHO_HTM_TB_2015​.28_eng.pdf?ua=1. Geneva: World Health Organization. 2015.

© World Health Organization 2018.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third-party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “The translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Bookshelf ID: NBK531413

Views

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...